Management of Chronic Lymphocytic Leukemia (CLL)

Diagnostic Criteria

The American Society of Clinical Oncology recommends that CLL diagnosis requires ≥5,000 monoclonal B lymphocytes/μL in peripheral blood, with flow cytometry confirmation of clonality and complete immunophenotyping 1, 2, 3, 4
The National Comprehensive Cancer Network suggests calculating the absolute B lymphocyte count if the total WBC is elevated, to confirm CLL diagnosis 1, 2
CLL diagnosis is confirmed if the absolute B lymphocyte count exceeds the diagnostic threshold of ≥5,000 cells/μL (5 × 10⁹/L) 1, 2, 3, 4

Flow cytometry is essential to demonstrate light chain restriction (kappa or lambda) and classic CLL immunophenotype: CD5+, CD19+, CD20+ (dim), CD23+, surface immunoglobulin (dim) 1, 2, 3, 4
The International Workshop on Chronic Lymphocytic Leukemia recommends assessing CD200 expression (positive in CLL) to differentiate from mantle cell lymphoma 1
Cytogenetic analysis using FISH panel is mandatory before initiating therapy to identify del(17p), del(11q), trisomy 12, and del(13q) 3, 4

The Binet staging system is used to classify CLL into three stages: A, B, and C, based on the number of lymph node regions involved, hemoglobin level, and platelet count 3, 4, 5
The Rai staging system is also used to classify CLL into five stages: 0, I, II, III, and IV, based on lymphocytosis, lymphadenopathy, organomegaly, anemia, and thrombocytopenia 3, 4, 5

The American Society of Clinical Oncology recommends a "watch and wait" approach for early-stage asymptomatic CLL, with serial monitoring every 3-6 months 1, 3, 4
Treatment is indicated for progressive cytopenias, massive or progressive lymphadenopathy or organomegaly, constitutional symptoms, or lymphocyte doubling time <6 months 1, 3, 4, 6, 5

The National Comprehensive Cancer Network suggests confirming cyclin D1 negativity to rule out mantle cell lymphoma, which requires different management 2, 3
Early treatment is not recommended for early-stage asymptomatic CLL, as it does not improve survival 1, 3, 4
Cytogenetic testing is essential before treatment to identify del(17p) and TP53 mutations, which require targeted therapies rather than chemoimmunotherapy 3, 4

CLL is defined by an absolute B‑lymphocyte count of ≥ 5,000 cells/µL (≥ 5 × 10⁹/L) in peripheral blood, confirmed by flow cytometry showing a clonal B‑cell population with the characteristic immunophenotype (CD5⁺, CD19⁺, dim CD20⁺, CD23⁺) 7, 8.

When the peripheral blood B‑cell count is < 5,000 cells/µL but a clonal B‑cell population is present without lymphadenopathy, organomegaly, cytopenias, or disease‑related symptoms, the condition is classified as monoclonal B‑lymphocytosis (MBL) rather than CLL 7.
MBL progresses to CLL requiring therapy at an estimated rate of 1–2 % per year 7.

Absolute lymphocyte count alone should not dictate therapy; patients with CLL rarely develop leukostasis even when counts exceed 100 × 10⁹/L 7, 9.
Initiation of treatment is not recommended solely on the basis of an elevated lymphocyte count; treatment should be reserved for the following clinical indications:

For patients achieving complete remission, the target peripheral blood lymphocyte count is < 4,000 cells/µL ( < 4 × 10⁹/L) and this level should be maintained for at least 2 months 10, 11.